Bicycle Therapeutics (BCYC)
(Delayed Data from NSDQ)
$23.05 USD
-0.14 (-0.60%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $22.98 -0.07 (-0.30%) 6:50 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BCYC 23.05 -0.14(-0.60%)
Will BCYC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BCYC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCYC
What Makes Bicycle Therapeutics (BCYC) a New Buy Stock
Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?
BCYC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year?
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
Is Bicycle Therapeutics (BCYC) Stock Outpacing Its Medical Peers This Year?
Other News for BCYC
Bicycle Therapeutics: Buy Rating Affirmed on Strong Q2 Financials and Promising Pipeline Developments
Morgan Stanley Remains a Hold on Bicycle Therapeutics (BCYC)
Oppenheimer Remains a Buy on Bicycle Therapeutics (BCYC)
Understanding Limitations in Analyst Recommendation Reports
Positive Clinical Prospects for Bicycle Therapeutics’ Drug Candidates at ESMO Congress May Strengthen Market Position